Gossamer Bio, Inc. GOSS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.43% | -55.42% | -57.74% | -58.17% | -58.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.43% | -55.42% | -57.74% | -58.17% | -58.02% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 32.43% | -55.42% | -57.74% | -58.17% | -58.02% |
| SG&A Expenses | 36.06% | 35.47% | 4.15% | 0.91% | -3.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.01% | 26.48% | 21.25% | 17.40% | 12.48% |
| Operating Income | -8.92% | -212.78% | -172.46% | -144.10% | -109.86% |
| Income Before Tax | 11.93% | -258.49% | -206.39% | -132.02% | -86.20% |
| Income Tax Expenses | 97.52% | -109.85% | -109.85% | -172.96% | -179.86% |
| Earnings from Continuing Operations | 9.74% | -252.07% | -201.39% | -117.96% | -71.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.74% | -252.07% | -201.39% | -117.96% | -71.60% |
| EBIT | -8.92% | -212.78% | -172.46% | -144.10% | -109.86% |
| EBITDA | -9.16% | -216.08% | -176.26% | -147.92% | -113.03% |
| EPS Basic | 7.41% | -248.92% | -200.01% | -116.23% | -57.21% |
| Normalized Basic EPS | -0.84% | -177.37% | -142.81% | -140.29% | -86.62% |
| EPS Diluted | -13.44% | -248.45% | -199.74% | -116.22% | -57.32% |
| Normalized Diluted EPS | -0.52% | -165.72% | -133.40% | -130.88% | -80.59% |
| Average Basic Shares Outstanding | 11.21% | 1.10% | 0.42% | 0.55% | 4.23% |
| Average Diluted Shares Outstanding | 12.18% | -0.25% | -0.93% | -0.80% | 2.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |